Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shanghai Junshi Biosciences Co., Ltd.

http://junshipharma.com/en/Index.html

Latest From Shanghai Junshi Biosciences Co., Ltd.

Junshi Joins China mRNA Mania Through Immorna JV

After immuno-oncology, mRNA is fast becoming a hot area in China as a flurry of biotechs from I-Mab to Kangtai partner with a little-known developer.

Deals China

Two Years On, China’s STAR Attracts Star Players But With New Hurdles

Created to take on Nasdaq in the US, the Shanghai Stock Exchange’s STAR Market is celebrating its two-year anniversary with star performers such as CanSino. But its viability as an alternative will be tested by BeiGene, which is set to start trading in Shanghai following dual listings in New York and Hong Kong, with the latter continuing to attract other biopharma IPOs.

China Financing

Toripalimab Set For ASCO Buzz With New Nasopharyngeal Data

Junshi and Coherus's PD-1 was already gaining attention for a particularly difficult cancer type even before the meeting, but new data add to its luster ahead of a potential US approval. 

Cancer Clinical Trials

EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market

EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.

ImmunoOncology Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Junshi Biosciences
UsernamePublicRestriction

Register